Evant

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Eimeria acervulina, sev 003, Eimeria maxima, sev 013, Eimeria mitis, sev 006, Eimeria praecox, sev 007, Eimeria tenella, sev 004

Available from:

Laboratorios Hipra, S.A.

ATC code:

QI01AN01

INN (International Name):

Coccidiosis vaccine live for chickens

Therapeutic group:

Piščanec

Therapeutic area:

V živo parazitske cepiva, Immunologicals za aves

Therapeutic indications:

Za aktivno imunizacijo piščancev od 1 dneva starosti za zmanjšanje poškodb črevesne in oocysts izhod povezana s coccidiosis zaradi Eimeria acervulina, Eimeria maxima, Eimeria mitis, Eimeria praecox in Eimeria tenella in za zmanjšanje kliničnih znakov (driske), ki je povezana z Eimeria acervulina, Eimeria maxima in Eimeria tenella.

Product summary:

Revision: 1

Authorization status:

Pooblaščeni

Authorization date:

2019-02-05

Patient Information leaflet

                                19
B. NAVODILO ZA UPORABO
20
NAVODILO ZA UPORABO
EVANT SUSPENZIJA IN VEHIKEL ZA PERORALNO PRŠILO ZA PIŠČANCE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za
sproščanje serij:
LABORATORIOS HIPRA, S.A.
Avda. la Selva 135
17170 Amer (Girona)
SPAIN
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
EVANT suspenzija in vehikel za peroralno pršilo za piščance
3.
NAVEDBA UČINKOVIN(E) IN DRUGE(IH) SESTAVIN
EVANT:
UČINKOVINE:
Vsak odmerek (0,007 ml) nerazredčenega cepiva vsebuje
_Eimeria acervulina, _
sev 003 ........................................... 332–450*
_Eimeria maxima, _
sev 013 ............................................... 196–265*
_Eimeria mitis, _
sev 006 ....................................................
293–397*
_Eimeria praecox, _
sev 007 ............................................... 293–397*
_Eimeria tenella, _
sev 004 ................................................. 276–374*
*Število sporuliranih oocist, ki izhajajo iz zgodaj zrelih
oslabljenih linij kokcidija, glede na postopke
_in vitro_
izdelovalca v času mešanja.
DODATEK IN POMOŽNE SNOVI:
VEHIKEL
HIPRAMUNE T
HIPRACELL
Dodatek
montanide IMS
redko tekoči parafin
Pomožne snovi
briljantno modro FCF (E133)
alurno rdeče AC (E129)
vanilin
Suspenzija: bela motna suspenzija.
Vehikel: temna rjavkasta raztopina.
4.
INDIKACIJA(E)
Za aktivno imunizacijo piščancev od 1. dne starosti za zmanjšanje
lezij v črevesju in tvorbe oocist,
povezanih s kokcidiozo, ki jo povzročajo paraziti
_Eimeria acervulina, Eimeria maxima, Eimeria mitis, _
_Eimeria praecox_
in
_Eimeria tenella_
, ter za zmanjšanje kliničnih znakov (diareje), povezanih s paraziti
_Eimeria acervulina_
,
_Eimeria maxima_
in
_Eimeria tenella._
Nastop imunosti: 14 dni po cepljenju.
Trajanje imunosti: 63 dni po cepljenju v okolju, ki dopušča
recikliranje oocist.
21
5.
KONTRAINDIKACIJE
Jih ni.
6.
NEŽELENI UČINK
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-03-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-03-2022
Public Assessment Report Public Assessment Report Bulgarian 01-03-2019
Patient Information leaflet Patient Information leaflet Spanish 04-03-2022
Public Assessment Report Public Assessment Report Spanish 01-03-2019
Patient Information leaflet Patient Information leaflet Czech 04-03-2022
Public Assessment Report Public Assessment Report Czech 01-03-2019
Patient Information leaflet Patient Information leaflet Danish 04-03-2022
Public Assessment Report Public Assessment Report Danish 01-03-2019
Patient Information leaflet Patient Information leaflet German 04-03-2022
Public Assessment Report Public Assessment Report German 01-03-2019
Patient Information leaflet Patient Information leaflet Estonian 04-03-2022
Public Assessment Report Public Assessment Report Estonian 01-03-2019
Patient Information leaflet Patient Information leaflet Greek 04-03-2022
Public Assessment Report Public Assessment Report Greek 01-03-2019
Patient Information leaflet Patient Information leaflet English 04-03-2022
Public Assessment Report Public Assessment Report English 01-03-2019
Patient Information leaflet Patient Information leaflet French 04-03-2022
Public Assessment Report Public Assessment Report French 01-03-2019
Patient Information leaflet Patient Information leaflet Italian 04-03-2022
Public Assessment Report Public Assessment Report Italian 01-03-2019
Patient Information leaflet Patient Information leaflet Latvian 04-03-2022
Public Assessment Report Public Assessment Report Latvian 01-03-2019
Patient Information leaflet Patient Information leaflet Lithuanian 04-03-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-03-2022
Public Assessment Report Public Assessment Report Lithuanian 01-03-2019
Patient Information leaflet Patient Information leaflet Hungarian 04-03-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 04-03-2022
Public Assessment Report Public Assessment Report Hungarian 01-03-2019
Patient Information leaflet Patient Information leaflet Maltese 04-03-2022
Public Assessment Report Public Assessment Report Maltese 01-03-2019
Patient Information leaflet Patient Information leaflet Dutch 04-03-2022
Public Assessment Report Public Assessment Report Dutch 01-03-2019
Patient Information leaflet Patient Information leaflet Polish 04-03-2022
Public Assessment Report Public Assessment Report Polish 01-03-2019
Patient Information leaflet Patient Information leaflet Portuguese 04-03-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 04-03-2022
Public Assessment Report Public Assessment Report Portuguese 01-03-2019
Patient Information leaflet Patient Information leaflet Romanian 04-03-2022
Public Assessment Report Public Assessment Report Romanian 01-03-2019
Patient Information leaflet Patient Information leaflet Slovak 04-03-2022
Public Assessment Report Public Assessment Report Slovak 01-03-2019
Patient Information leaflet Patient Information leaflet Finnish 04-03-2022
Public Assessment Report Public Assessment Report Finnish 01-03-2019
Patient Information leaflet Patient Information leaflet Swedish 04-03-2022
Public Assessment Report Public Assessment Report Swedish 01-03-2019
Patient Information leaflet Patient Information leaflet Norwegian 04-03-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 04-03-2022
Patient Information leaflet Patient Information leaflet Icelandic 04-03-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 04-03-2022
Patient Information leaflet Patient Information leaflet Croatian 04-03-2022
Public Assessment Report Public Assessment Report Croatian 01-03-2019

View documents history